In a regulatory filing, AbbVie (ABBV) disclosed that reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are ...

(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition-related expenses. The company expects adjusted profit in the range of ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on AbbVie (ABBV – Research Report), with a price target ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

What happens when biotech partners end up on opposite sides of a courtroom? That’s the question now looming over AbbVie and Genmab, two biotech heavyweights whose billion-dollar collaboration helped ...

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 29 trades. If we consider the specifics of each trade ...